THE AMA CPT Issues a Category III Code Applicable to Orlucent Inc.’s Molecular Test for Biological Activity in Suspicious Nevi

Los Gatos, CA, May 6, 2021 – Orlucent, Inc., a privately held medical device company, today announced that the AMA CPT issued a category III code applicable to its fluorescent molecular imaging test. Establishment of the code was granted with support of the CPT Advisors for the American Academy of Dermatology. Category III codes are designed for emerging technologies and can be established before FDA clearance is granted. There is growing acceptance of these codes among physicians and healthcare plans, and the AMA actively promotes their use. 0700T – Molecular fluorescent imaging of suspicious nevus; first lesion; 0701T – Molecular fluorescent imaging of suspicious nevus; each additional lesion